Benchling is the leader in cloud-based informatics for life science R&D. The company offers a unified R&D platform purpose-built for biologics, including solutions for Lab Notebook, Molecular Biology, Bioregistration, Sample Tracking, and Request & Workflow Management. Benchling is used by over 100,000 scientists globally throughout multinational pharmaceutical corporations, emerging biotechnology companies, and major research institutions.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 06/14/18 | $14,500,000 | Series B |
Benchmark Capital F-Prime Capital Partners Fidelity Investments Thrive Capital | undisclosed |
| 07/25/19 | $34,500,000 | Series C |
Benchmark Capital Lead Edge Capital Menlo Ventures Thrive Capital Y Combinator | undisclosed |
| 05/28/20 | $50,000,000 | Series D |
Alkeon Capital Benchmark Capital ICONIQ Capital Lux Capital Management Spark Capital Thrive Capital | undisclosed |
| 04/14/21 | $200,000,000 | Series E |
Alkeon Capital Altimeter Capital Benchmark Capital Byers Capital Elad Gil ICONIQ Capital Lead Edge Capital Lux Capital Menlo Ventures Spark Capital Thrive Capital | undisclosed |
| 11/21/21 | $100,000,000 | Series F |
Altimeter Capital Franklin Templeton Lone Pine Tiger Global Management | $6,100,000,000 |
